Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
TSVT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-1.08
vs -3.20
Q2.23
N/A
-0.83
vs -2.02
Q3.23
N/A
-1.00
vs -1.76
Q4.23
N/A
-1.11
vs -0.60
Q1.24
N/A
-0.81
vs -1.08
Q2.24
N/A
-0.29
vs -0.83
Q3.24
N/A
-0.18
vs -1.00
Q4.24
N/A
-0.31
vs -1.11
Q1.25
N/A
-0.17
vs -0.81
Q2.25
N/A
-0.15
vs -0.29
Sales Growth
YoY
Current
Estimates
Q1.23
+394%
41.6M vs 8.4M
Q2.23
+167%
36M vs 13.5M
Q3.23
-10%
12M vs 13.4M
Q4.23
-81%
10.7M vs 56.2M
Q1.24
-70%
12.4M vs 41.6M
Q2.24
-75%
9M vs 36M
Q3.24
+12%
13.5M vs 12M
Q4.24
-73%
2.9M vs 10.7M
Q1.25
+12%
14M vs 12.4M
Q2.25
+50%
13.4M vs 9M
Return on Equity
QoQ
Q1.23
-11%
-0.11
vs -0.07
Q2.23
-11%
-0.11
vs -0.11
Q3.23
-23%
-0.23
vs -0.11
Q4.23
-22%
-0.22
vs -0.23
Q1.24
-25%
-0.25
vs -0.22
Q2.24
+11%
0.11
vs -0.25
Q3.24
-4%
-0.04
vs 0.11
Q4.24
-9%
-0.09
vs -0.04
Institutionnal Ownership
QoQ
Q1.23
144
144
vs 138
4%
Q2.23
151
151
vs 144
5%
Q3.23
142
142
vs 151
-6%
Q4.23
120
120
vs 142
-15%
Q1.24
119
119
vs 120
-1%
Q2.24
115
115
vs 119
-3%
Q3.24
116
116
vs 115
1%
Q4.24
116
116
vs 116
NA
Quote Panel
Key Metrics
zacks.com
13 hours ago
prnewswire.com
13 hours ago
businesswire.com
16 hours ago
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
Relative Strenght
96
Volume Buzz
-76%
Earning Acce
No
Dist 52w H.
6%Relative Strength
TSVT
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
2240%2025-Revenue
-8%2025-EPS
-189%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Hold
Price Target
5.00(0.00%)
Number of analyst
1
Last analyst upgrade/downgrade
Goldman Sachs
downgradePrevious: Buy
2024-06-06
Now: Sell
Leerink Partners
upgradePrevious: Not converted
2024-01-31
Now: Outperform
Guggenheim
downgradePrevious: Not converted
2023-09-13
Now: Neutral
Goldman Sachs
initialisePrevious: Not converted
2022-05-02
Now: Buy
